Investigators with the UNC Institute for Global Health and Infectious Diseases (IGHID) are participating in the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco, California, March 9-12. The CROI Preliminary Program is available here. Following is a list of contributing activities from a few of our members.
Sunday, March 9
- For new investigators and trainees, Joseph J. Eron, will lead the Scott M. Hammer Workshop:
HIV Cure Research: State of the Art and Navigating Presentations at CROI 2025 - Concurrently, Cecilia Kanyama will serve as a panelist for the workshop: Antiretroviral Therapy: Case-Based Panel Discussion
(8:30am – 12:30pm PT)
Tuesday, March 11
- Sara Rutstein will present the poster:
Developing Analytic Strategies to Investigate Long-Acting Injectable Antiretroviral Effectiveness
(2:30 – 4pm PT)
Other posters presented by IGHID members include:
- Nancie Archin, David Margolis, and Ed Browne: A targeted CRISPR screen identifies ETS1 as a regulator of HIV latency
- David Margolis, Edward Browne: NF-kB dependent Gene Expression and Plasma IL-1b, TNFa and GCSF drive transcriptomic diversity and CD4:CD8 Ratio in People with HIV on ART
- David Margolis, Anne-Marie Turner, Nancie Archin, and Edward Browne: Characterization of the gastrointestinal-resident latent HIV-1 reservoir with single-cell RNA seq
- Weiming Tang: Digital Strategy to improve PrEP adherence among MSM: A Stepped-wedge Randomized Trial in China, and Leveraging Community to Provide PrEP to Key Population in China: Results From a PrEP Clinical Trial
- Cindy Gay, Sofia Mariano, Caroline Baker, Susan Pedersen, Joseph Eron, David Margolis, Michael Hudgens, and Nilu Goonetilleke: ChAdOx1.HIVconsvX and MVA.HIVconsvX Vaccination is Safe and Immunogenic in PWH on ART – THE CM STUDY
- Cindy Gay, Sofia Mariano, Caroline Baker, Susan Pedersen, Joseph Eron, David Margolis, Michael Hudgens, and Nilu Goonetilleke: Age inversely correlates with T cell response to MVA.HIVconsvX vaccination in PWH on ART– THE M&M STUDY
- Martina Kovarova: Development of a Two-Drug-Long-Acting Removable Formulation for HIV suppression
Wednesday, March 12
- Sarah Rutstein will moderate the session: Expanding the Prevention Toolbox
(10am – 12pm PT)
The Conference on Retroviruses and Opportunistic Infections (CROI) was established in 1993 to provide a forum for basic scientists and clinical investigators to present, discuss, and critique their investigations into the epidemiology and biology of human retroviruses and associated diseases. The synergy of basic science and clinical investigation has been a major contributor to the success of the meeting. CROI has facilitated the presentation of important discoveries in the field, thereby accelerating progress in HIV and AIDS research. CROI highlights the latest research in HIV, hepatitis viruses, SARS-CoV-2 (including long COVID), mpox, and their related conditions.